Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder-Reference-Cited by-同舟云学术

Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder

Published:2023-08-07 Issue:15 Volume:24 Page:1715-1723
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Fagiolini Andrea¹,Cardoner Narcis²,Pirildar Sebnem³,Ittsakul Pichai⁴,Ng Bernardo⁵,Duailibi Kalil⁶,El Hindy Nasser⁷

Affiliation:

1. Department of Molecular Medicine, University of Siena School of Medicine, Siena, Italy

2. Department of Psychiatry and Legal Medicine, Hospital de la Santa Creu I Sant Pau, Biomedical Research Institute Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona (UAB), CIBERSAM, Carlos III Health Institute, Madrid, Spain

3. Department of Mental Health and Diseases, Ege University Medical School, Izmir, Turkey

4. Department of Psychiatry, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

5. Mexican Consortium of Neuropsychopharmacology, Mexico, Sun Valley Research Center, Imperial, California, USA

6. Department of Psychiatry, Santo Amaro University, São Paulo, Brazil

7. American Center Neurology and Psychiatry, Dubai, United Arab Emirates

Funder

Viatris

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2023.2242264

Reference67 articles.

1. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

2. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019;GBD 2019 Mental Disorders Collaborators;Lancet Psychiatry,2022

3. Addressing the burden of mental, neurological, and substance use disorders: key messages from disease control priorities, 3rd edition;Patel V;Lancet,2016

4. World Health Organization. The impact of the COVID-19 pandemic on noncommunicable disease resources and services: results of a rapid assessment2020. https://www.who.int/publications/i/item/9789240010291

5. World Health Organization. Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic: November-December 20212022. https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-EHS_continuity-survey-2022.1

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving trends of pharmaceutical poisonings associated with QRS complex prolongation;Clinical Toxicology;2024-08-28

2. A multicenter retrospective study of antidepressant use in outpatient clinics in China pre- and post-COVID;International Journal of Clinical Pharmacy;2024-08-14

3. Improving Mental Health Outcomes in Patients with Major Depressive Disorder in the Gulf States: A Review of the Role of Electronic Enablers in Monitoring Residual Symptoms;Journal of Multidisciplinary Healthcare;2024-07

4. A multicenter, retrospective study of the current status of antidepressant prescription use in outpatient settings in China;2024-05-13

5. Effect of venlafaxine on anhedonia and amotivation in patients with major depressive disorder;CNS Spectrums;2024-04-30